Q3 Earnings Estimate for ACHV Issued By HC Wainwright

Key Points

• HC Wainwright has issued a Q3 2025 earnings estimate of ($0.23) per share for Achieve Life Sciences, maintaining a "Buy" rating with a price target of $12.00.
• Achieve Life Sciences reported ($0.37) EPS in its last quarterly earnings, meeting the consensus estimate, while current full-year earnings are expected to be ($1.17) per share.
• The company has seen significant interest from institutional investors, with several firms increasing their stakes, including Tower Research Capital's 185.8% increase during the 4th quarter.

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Free Report) - HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for shares of Achieve Life Sciences in a research note issued to investors on Thursday, August 21st. HC Wainwright analyst B. Folkes forecasts that the biopharmaceutical company will earn ($0.23) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $12.00 price target on the stock. The consensus estimate for Achieve Life Sciences' current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Achieve Life Sciences' Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($1.13) EPS, FY2026 earnings at ($1.15) EPS, FY2027 earnings at ($0.25) EPS, FY2028 earnings at $0.82 EPS and FY2029 earnings at $1.51 EPS.

Achieve Life Sciences Stock Up 1.0%

ACHV opened at $2.92 on Monday. The business has a 50 day moving average price of $2.69 and a two-hundred day moving average price of $2.80. The company has a quick ratio of 6.64, a current ratio of 6.64 and a debt-to-equity ratio of 0.21. The company has a market cap of $149.21 million, a PE ratio of -2.00 and a beta of 1.30. Achieve Life Sciences has a 52 week low of $1.84 and a 52 week high of $5.31.

Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, meeting the consensus estimate of ($0.37).

Institutional Trading of Achieve Life Sciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC raised its stake in shares of Achieve Life Sciences by 185.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,545 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 4,905 shares in the last quarter. AQR Capital Management LLC purchased a new position in shares of Achieve Life Sciences during the 1st quarter worth approximately $32,000. Squarepoint Ops LLC purchased a new position in shares of Achieve Life Sciences during the 4th quarter worth approximately $62,000. Sender Co & Partners Inc. purchased a new position in shares of Achieve Life Sciences during the 2nd quarter worth approximately $56,000. Finally, Bank of America Corp DE raised its stake in shares of Achieve Life Sciences by 39.9% during the 2nd quarter. Bank of America Corp DE now owns 33,731 shares of the biopharmaceutical company's stock worth $76,000 after buying an additional 9,617 shares in the last quarter. 33.52% of the stock is owned by hedge funds and other institutional investors.

About Achieve Life Sciences

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.